B-cell chronic lymphocytic leukemia (B-CLL) is considered an accumulative disease of antigen-naive CD5+ B lymphocytes that circulate in the resting state. However, to evaluate the possibility that B-CLL cells resemble antigen-experienced and activated B cells, we analyzed the expression of markers of cellular activation and differentiation on CD5+CD19+ cells from B-CLL patients and from age-matched healthy donors. The leukemic cells from all B-CLL patients, including those that lack significant numbers of V gene mutations, bear the phenotype of activated B cells based on the overexpression of the activation markers CD23, CD25, CD69, and CD71 and the underexpression of CD22, Fcγ receptor IIb, CD79b, and immunoglobulin D that are down-regulated by cell triggering and activation. Furthermore, these leukemic cells resemble antigen-experienced lymphocytes in the underexpression of molecules that are down-regulated by cell triggering and in the uniform expression of CD27, an identifier of memory B cells. A comparison of the phenotypes of B-CLL patients with and without immunoglobulin V gene mutations suggests that the 2 subgroups differ both in specific marker expression (CD69, CD71, CD62 L, CD40, CD39, and HLA-DR) and in the time since antigenic stimulation, based on the reciprocal relationship of CD69 and CD71 expression. These findings imply that the leukemic cells from all B-CLL cases (irrespective of V gene mutations) exhibit features of activated and of antigen-experienced B lymphocytes and that the B-CLL cells that differ in immunoglobulin V genotype may have different antigen-encounter histories.

B-cell chronic lymphocytic leukemia (B-CLL) has been viewed as a homogeneous disease arising from the accumulation of naive, antigen-inexperienced B lymphocytes that circulate in the resting state (reviewed in Caligaris-Cappio et al1). Indeed, the view that B-CLL cells are antigen-naive and resting is consistent with their appearance as small lymphocytes with high nuclear-to-cytoplasmic ratios2 and their surface membrane coexpression of immunoglobulin M (IgM) and IgD, which usually marks virgin B cells.3 

Nonetheless, the concepts that B-CLL cells are homogeneous and similar among patients and that they resemble antigen-naive and resting B cells are currently being called into question. For example, the documentation of somatic mutations in the leukemic lymphocytes of greater than 50% of these patients4-7 indicates that B-CLL cells are not necessarily similar among patients and that the disease is not homogeneous in this respect. In fact, B-CLL cases can be divided into at least 2 subgroups on the basis of the presence or absence of significant numbers of V gene mutations; these subgroups identify patients that follow strikingly dissimilar clinical courses.8,9 Since the induction of immunoglobulin V gene mutations requires cellular activation and maturation induced by antigen receptor engagement,10 11 B-CLL cells with immunoglobulin V gene mutations resemble antigen-experienced B cells that at one point in their evolution were activated and therefore are not antigen-naive. On the basis of this reasoning, the question arises as to whether B-CLL cells that exhibit immunoglobulin V genes with germ line–like sequences are indeed resting and antigen-naive or whether they also represent B cells that were stimulated out of the resting state by antigen but that did not accumulate mutations.

In addition, other data suggest that in vivo activation, albeit abortive, can occur in B-CLL. For example, B-CLL cells can express elevations of cyclin D2 without increases of the other cyclins that follow in cell cycle progression.12 Furthermore, B-CLL cells can exhibit constitutive translocation of nuclear factor of activated T cells (NF-ATp)13 and phosphorylation of signal transducer and activator of transcription 1 (STAT-1) and STAT-3.14 Finally, most B-CLL cells express CD23, a cell surface marker acquired after B-cell activation.15-18 These findings suggest that certain B-CLL cells or their precursors may have been triggered and may have attempted to traverse the cell cycle, and may therefore not be resting or antigen-naive.

To examine further the possibility that the leukemic cells from all B-CLL cases are antigen-experienced and exist in an activated state, we analyzed the expression of a panel of surface markers that define cellular activation and differentiation in a large cohort of B-CLL patients. The data indicate that all B-CLL cells, including those from patients with unmutated immunoglobulin V genes, bear the surface membrane phenotype of activated and antigen-experienced B lymphocytes. Furthermore, comparative analyses of the unmutated and mutated subgroups indicate different activation phenotypes, suggesting that they resemble B cells that differ in the time since their antigenic stimulation and, possibly, B cells activated by different activation stimuli.

Patients and healthy donors

The Institutional Review Boards of North Shore University Hospital (Manhasset, NY) and Long Island Jewish Medical Center (New Hyde Park, NY) approved these studies. Informed consent was provided by all participants in accordance with the Declaration of Helsinki. A total of 61 cases diagnosed as B-CLL were studied. Laboratory data on a subset of these cases have been reported earlier.3,7,8 Patients were selected for the present study on the basis of the availability of DNA sequences for both the immunoglobulin VH and VL genes in each case.5,8,19 Patients lacking allelic exclusion of immunoglobulin V genes20 were not included. As a source of normal lymphocytes, leukocyte-enriched fractions from the blood of age-matched healthy volunteers were purchased from Long Island Blood Services (Melville, NY). These samples did not contain detectable titers of human immunodeficiency virus or hepatitis B virus antibodies.

Isolation of peripheral blood mononuclear cells

Peripheral blood mononuclear cells (PBMCs) were separated from heparinized venous blood of the B-CLL patients and from leukocyte fractions of the healthy donors by density gradient centrifugation using Ficoll-Paque (Pharmacia LKB Biotechnology, Piscataway, NJ). PBMCs were cryopreserved with a programmable cell-freezing machine (Cryomed, Mt Clemens, MI) and thawed at the time of analysis.

Cellular immunophenotypic analyses

The panel of antibodies described in Table1 was used to analyze subsets of CD5+ B cells expressing various surface markers that identify the activation/differentiation state of cells. Initially, each antibody preparation was titrated to determine the amount that identified positive cells with the optimal mean fluorescence intensity; this amount was then used in subsequent studies. For direct immunofluorescent analyses, PBMCs were suspended at a concentration of 107 cells per milliliter in fluorescent-activated cell sorter (FACS) buffer (1% bovine serum albumin and 0.1% sodium azide in phosphate-buffered saline [PBS], pH 7.2) and 50 μL cells were added to the standardized volumes of fluorochrome-conjugated antibodies. The cells were incubated for 30 minutes at 4°C, and excess, unbound antibodies were removed by 2 washes with FACS buffer. Following these washes, cells were fixed with PBS containing 2% formaldehyde for at least 2 hours before analysis on a flow cytometer (FACScan, Becton Dickinson, San Jose, CA). The CellQuest program was used for statistical analysis of the acquired data.

Table 1.

Fluorochrome-conjugated and unconjugated antibodies used in immunophenotyping

Molecule with which
antibody was reactive
FluorochromeManufacturer/source
CD5 FITC, PE Becton Dickinson (San Jose, CA) 
CD19 APC Becton Dickinson 
CD22 FITC Immunotech (Westbrook, ME) 
CD23 FITC Immunotech  
CD24 FITC Pharmingen (La Jolla, CA)  
CD25 FITC Immunotech 
CD27 FITC Pharmingen  
CD30 FITC Pharmingen 
CD38 PE Becton Dickinson  
CD39 PE Pharmingen 
CD40 FITC Pharmingen  
CD40L FITC Ancell (Bayport, MN)  
CD44 FITC Pharmingen  
CD45RA FITC Immunotech 
CD62L FITC Pharmingen  
CD69 FITC Becton Dickinson 
CD71 FITC Becton Dickinson  
CD72 FITC Pharmingen 
CD77 Unconjugated Immunotech  
CD79b PE Immunotech 
CD80 PE Becton Dickinson  
CD86 FITC Pharmingen 
CD95 FITC MBL (Nagoya, Japan) 
HLA-DR FITC Pharmingen  
Syndecan-1 FITC Serotec (Oxford, United Kingdom)  
Murine IgG FITC Biosource International (Camarillo, CA)  
Rat IgM FITC Biosource International  
Human IgM, IgG, IgA, and IgD FITC Southern Biotechnology Associates (Birmingham, AL)  
Human kappa light chain FITC Becton Dickinson  
Human lambda light chain FITC Becton Dickinson  
FcγRII (II1A5) Pure Dr Jurgen Frey (Weinrich et al64)  
FcγRIIb (II8D2) Pure Dr Jurgen Frey (Weinrich et al64
Molecule with which
antibody was reactive
FluorochromeManufacturer/source
CD5 FITC, PE Becton Dickinson (San Jose, CA) 
CD19 APC Becton Dickinson 
CD22 FITC Immunotech (Westbrook, ME) 
CD23 FITC Immunotech  
CD24 FITC Pharmingen (La Jolla, CA)  
CD25 FITC Immunotech 
CD27 FITC Pharmingen  
CD30 FITC Pharmingen 
CD38 PE Becton Dickinson  
CD39 PE Pharmingen 
CD40 FITC Pharmingen  
CD40L FITC Ancell (Bayport, MN)  
CD44 FITC Pharmingen  
CD45RA FITC Immunotech 
CD62L FITC Pharmingen  
CD69 FITC Becton Dickinson 
CD71 FITC Becton Dickinson  
CD72 FITC Pharmingen 
CD77 Unconjugated Immunotech  
CD79b PE Immunotech 
CD80 PE Becton Dickinson  
CD86 FITC Pharmingen 
CD95 FITC MBL (Nagoya, Japan) 
HLA-DR FITC Pharmingen  
Syndecan-1 FITC Serotec (Oxford, United Kingdom)  
Murine IgG FITC Biosource International (Camarillo, CA)  
Rat IgM FITC Biosource International  
Human IgM, IgG, IgA, and IgD FITC Southern Biotechnology Associates (Birmingham, AL)  
Human kappa light chain FITC Becton Dickinson  
Human lambda light chain FITC Becton Dickinson  
FcγRII (II1A5) Pure Dr Jurgen Frey (Weinrich et al64)  
FcγRIIb (II8D2) Pure Dr Jurgen Frey (Weinrich et al64

Ig indicates immunoglobulin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.

The expression of CD77, Fcγ receptor II (FcγRII), and FcγRIIb was determined by indirect immunofluorescence. PBMCs were incubated with primary antibody for 30 minutes. Following 2 washes with FACS buffer, cells were incubated with fluorochrome-conjugated secondary antibodies (fluorescein isothiocyanate [FITC]–conjugated goat anti–rat IgM for CD77, and FITC-conjugated goat anti–mouse IgG1 for FcγRII and FcγRIIb), and anti-CD5–phycoerythrin and anti-CD19–allophycocyanin. Following incubation and washing, the cells were fixed and analyzed as above.

Statistical analyses

The percentages of normal CD5+ B cells expressing various surface markers were compared with those of the leukemic cells from the B-CLL cases studied. The statistical significance of the observed differences was deduced by means of the Mann-Whitney test. Differences in the density of expression of surface markers were similarly analyzed to determine statistical significance.

Comparison of surface membrane phenotypes of B-CLL cells and of normal peripheral blood CD5+ B cells

CD5+ B cells from B-CLL patients and age-matched healthy individuals were studied by 3-color immunofluorescence for expression of surface molecules that indicate different stages of cellular activation or differentiation. The percentages of B-CLL cells and normal CD5+ B cells expressing CD24, CD30, CD44, CD45RA, CD77, CD86, HLA-DR, and syndecan-1 were comparable. However, significantly higher numbers of B-CLL cells expressed the markers CD23, CD25, CD27, CD39, CD69, and CD71 (Figure1). In contrast, significantly fewer B-CLL cells expressed CD22, CD32/FcγRIIb, CD38, CD40, CD154/CD40 ligand (CD154/CD40L), CD62L, CD72, CD79b, CD80, and CD95 (Figure2).

Fig. 1.

Expression of surface membrane markers on B-CLL cells and normal CD5+ B cells.

Surface membrane markers overexpressed on B-CLL cells as compared with normal CD5+ B cells. PBMCs from B-CLL cases and age-matched healthy donors were analyzed for marker expression on CD5+CD19+ cells by means of 3-color immunofluorescence. (A) Representative flow cytometric profiles of expression of these markers on B cells from a 67-year-old healthy donor (N39) and a B-CLL patient (CLL 308). (B) Paired bars depict the mean ± SE of the percentage of CD5+CD19+cells expressing these markers in 61 (51 IgM+ and 10 IgG+) B-CLL patients and 20 age-matched healthy controls studied. B-CLL cells express significantly higher percentages (P < .0001) of CD27, CD39, CD23, CD25, CD69, and CD71 than normal CD5+CD19+ cells. The expression of these markers was variable both in the patients and in the markers, with the greatest variability seen for CD25. The SE and the SD for these markers ranged from 1.7 to 3.6 and from 13.1 to 28.0, respectively.

Fig. 1.

Expression of surface membrane markers on B-CLL cells and normal CD5+ B cells.

Surface membrane markers overexpressed on B-CLL cells as compared with normal CD5+ B cells. PBMCs from B-CLL cases and age-matched healthy donors were analyzed for marker expression on CD5+CD19+ cells by means of 3-color immunofluorescence. (A) Representative flow cytometric profiles of expression of these markers on B cells from a 67-year-old healthy donor (N39) and a B-CLL patient (CLL 308). (B) Paired bars depict the mean ± SE of the percentage of CD5+CD19+cells expressing these markers in 61 (51 IgM+ and 10 IgG+) B-CLL patients and 20 age-matched healthy controls studied. B-CLL cells express significantly higher percentages (P < .0001) of CD27, CD39, CD23, CD25, CD69, and CD71 than normal CD5+CD19+ cells. The expression of these markers was variable both in the patients and in the markers, with the greatest variability seen for CD25. The SE and the SD for these markers ranged from 1.7 to 3.6 and from 13.1 to 28.0, respectively.

Close modal
Fig. 2.

Expression of surface membrane markers on B-CLL cells and normal CD5+ B cells.

Surface membrane markers underexpressed on B-CLL cells as compared with normal CD5+ B cells. PBMCs from B-CLL patients and age-matched healthy donors were analyzed for marker expression on CD5+CD19+ cells. (A) Representative flow cytometric profiles of expression of these markers on B cells from a 67-year-old healthy donor (N39) and CLL 308. (B) Paired bars depict the mean ± SE of the percentage of CD5+CD19+ cells expressing these markers in 51 IgM+ and 10 IgG+ B-CLL patients and 20 age-matched healthy controls. B-CLL cells expressed significantly lower percentages (P < .0001) of CD40, CD72, CD22, CD79b, CD62L, CD38, FcγRIIb, CD40L, CD95, and CD80 than normal CD5+CD19+ cells. The expression of these markers was variable both in the patients and in the markers, with the greatest variability seen for CD38. The SE and the SD for these markers ranged from 1.2 to 4.7 and from 8.9 to 35.5, respectively.

Fig. 2.

Expression of surface membrane markers on B-CLL cells and normal CD5+ B cells.

Surface membrane markers underexpressed on B-CLL cells as compared with normal CD5+ B cells. PBMCs from B-CLL patients and age-matched healthy donors were analyzed for marker expression on CD5+CD19+ cells. (A) Representative flow cytometric profiles of expression of these markers on B cells from a 67-year-old healthy donor (N39) and CLL 308. (B) Paired bars depict the mean ± SE of the percentage of CD5+CD19+ cells expressing these markers in 51 IgM+ and 10 IgG+ B-CLL patients and 20 age-matched healthy controls. B-CLL cells expressed significantly lower percentages (P < .0001) of CD40, CD72, CD22, CD79b, CD62L, CD38, FcγRIIb, CD40L, CD95, and CD80 than normal CD5+CD19+ cells. The expression of these markers was variable both in the patients and in the markers, with the greatest variability seen for CD38. The SE and the SD for these markers ranged from 1.2 to 4.7 and from 8.9 to 35.5, respectively.

Close modal

Although the percentage of leukemic cells expressing CD38 among all the B-CLL patients studied was lower than the percentage of normal CD5+ B cells, when the 2 subgroups of B-CLL cases, defined on the basis of immunoglobulin V gene mutation status (see below), were independently compared with the CD5+ B cells from normal donors, the data were different. Specifically, in regard to the percentages of cells expressing CD38, the unmutated cases were similar to the normal CD5+ B cells (P = .083), whereas the mutated cases were different from normal CD5+ B cells (P < .001).

To measure the density of expression of an individual marker, we calculated the ratio of the mean fluorescence intensity (MFIR) of antibody binding to the surface molecule relative to the mean fluorescence intensity of nonspecific binding of a corresponding isotype “control” antibody. B-CLL cells and normal CD5+B cells expressed CD23, CD25, CD69, and CD71 at comparable densities (data not shown). However, CD5 and CD27 were expressed on B-CLL cells at significantly higher densities compared with normal CD5+cells, whereas CD22, FcγRIIb, and CD38 were expressed at significantly lower densities (Figure 3). The density of CD38 expression was less than that of normal CD5+ B cells, not only when the B-CLL cases were considered as a whole (P < .001) but also when they were segregated into unmutated (P < .001) and mutated (P < .01) subgroups.

Fig. 3.

Comparison of density of expression of surface membrane markers by B-CLL cells and normal CD5+ B cells.

The density of expression of CD5, CD27, CD38, CD22, FcγRIIb, IgD, and IgM on B-CLL cells was compared with that on CD5+CD19+ cells from age-matched controls. The density of expression of a membrane molecule was estimated as a ratio of specific-to-nonspecific binding of isotype “control” antibody and is expressed as the MFIR on the y-axis. Dark lines represent staining of cells using antibodies to the molecules listed whereas the thin lines represent the staining with isotype-matched control antibodies. (A) Representative flow cytometric profiles of expression of these markers on CD5+CD19+ B cells from a 67-year-old healthy donor (N39) and CLL 308. (B) Paired bars depict the mean ± SE of the MFIR of expression of these markers on CD5+CD19+ cells in 51 IgM+ B-CLL patients and 20 age-matched healthy controls. Although the IgG+ B-CLL patients expressed CD5, CD27, CD38, CD22, and FcγRIIb at densities identical to those of IgM+B-CLL patients, the data in this Figure do not include the IgG+ B-CLL patients since they do not express either smIgM (smIgM) or smIgD. All differences were statistically significant (P < .001).

Fig. 3.

Comparison of density of expression of surface membrane markers by B-CLL cells and normal CD5+ B cells.

The density of expression of CD5, CD27, CD38, CD22, FcγRIIb, IgD, and IgM on B-CLL cells was compared with that on CD5+CD19+ cells from age-matched controls. The density of expression of a membrane molecule was estimated as a ratio of specific-to-nonspecific binding of isotype “control” antibody and is expressed as the MFIR on the y-axis. Dark lines represent staining of cells using antibodies to the molecules listed whereas the thin lines represent the staining with isotype-matched control antibodies. (A) Representative flow cytometric profiles of expression of these markers on CD5+CD19+ B cells from a 67-year-old healthy donor (N39) and CLL 308. (B) Paired bars depict the mean ± SE of the MFIR of expression of these markers on CD5+CD19+ cells in 51 IgM+ B-CLL patients and 20 age-matched healthy controls. Although the IgG+ B-CLL patients expressed CD5, CD27, CD38, CD22, and FcγRIIb at densities identical to those of IgM+B-CLL patients, the data in this Figure do not include the IgG+ B-CLL patients since they do not express either smIgM (smIgM) or smIgD. All differences were statistically significant (P < .001).

Close modal

Although the density of expression of surface membrane IgM (smIgM) and smIgD on B-CLL cells was significantly lower than on normal CD5+ B cells (P < .001; Figure 3), the ratio of surface IgM-to-IgD on B-CLL cells was significantly higher (mean, 1.58) compared with normal CD5+ B cells (mean, 0.66;P < .05).

Comparison of surface phenotypes of IgM+ and IgG+ B-CLL patients

Although most B-CLL patients bear smIgM, some express non-IgM isotypes.21 22 When we analyzed the same markers on the 10 IgG+ B-CLL patients in our cohort, we found significantly higher percentages of cells expressing CD27 (mean, 97.5% versus 85.6%), CD62L (mean, 59.7% versus 34.5%), and CD72 (mean, 89.8% versus 75.3%), and significantly lower percentages of cells expressing syndecan-1 (mean, 2.7% versus 14.9%), as compared with the 51 IgM+ cases (P < .001). These markers were expressed at similar densities in the IgG+ and IgM+ cases.

Phenotypic differences in B-CLL cases grouped by immunoglobulin V gene mutation status

Because immunoglobulin V gene mutation status segregates B-CLL cases into 2 subgroups7 with significantly different clinical courses,8 9 we compared the phenotypes of our B-CLL cases stratified in this manner. The cases were classified as unmutated if both their immunoglobulin VH and their VL genes differed by less than 2% from the most similar germ line counterpart; they were classified as mutated if either their immunoglobulin VH or their VL genes differed by 2% or more from the corresponding germ line gene. The unmutated group contained significantly higher percentages of leukemic cells expressing CD38, CD69, and CD40, whereas the mutated group contained significantly higher percentages of B-CLL cells expressing CD62L, CD71, and CD39 (Figure 4).

Fig. 4.

Comparison of surface membrane phenotypes of IgM+ B-CLL cases grouped on the basis of immunoglobulin V gene mutation.

PBMCs from 51 IgM+ B-CLL cases were analyzed for the expression of CD38, CD39, CD40, CD62L, CD69, and CD71 on CD5+CD19+ cells. The B-CLL cases were segregated into 2 groups: unmutated, in which the expressed immunoglobulin V genes showed less than a 2.0% difference from the most similar germ line gene, and mutated, in which the expressed immunoglobulin V genes showed a 2.0% or greater difference from the most similar germ line. The mean ± SE of the percentages of CD5+CD19+ cells expressing these markers in the unmutated and mutated cases are represented. All differences were statistically significant (P < .001).

Fig. 4.

Comparison of surface membrane phenotypes of IgM+ B-CLL cases grouped on the basis of immunoglobulin V gene mutation.

PBMCs from 51 IgM+ B-CLL cases were analyzed for the expression of CD38, CD39, CD40, CD62L, CD69, and CD71 on CD5+CD19+ cells. The B-CLL cases were segregated into 2 groups: unmutated, in which the expressed immunoglobulin V genes showed less than a 2.0% difference from the most similar germ line gene, and mutated, in which the expressed immunoglobulin V genes showed a 2.0% or greater difference from the most similar germ line. The mean ± SE of the percentages of CD5+CD19+ cells expressing these markers in the unmutated and mutated cases are represented. All differences were statistically significant (P < .001).

Close modal

The density of expression of these molecules was comparable in the 2 groups. This was also true for CD38, despite the marked difference between the unmutated and mutated groups (P = .39) in the percentage of cells expressing this molecule. In contrast, HLA-DR was expressed at a significantly higher density on the leukemic cells of the unmutated B-CLL group (P < .01; Figure5).

Fig. 5.

Comparison of density of HLA-DR expression on B-CLL cells and normal CD5+ B cells.

PBMCs from 61 B-CLL cases and 20 age-matched normal donors were analyzed for the expression of HLA-DR on CD5+CD19+ cells. Bars represent the mean ± SE of the MFIR of HLA-DR expression on CD5+CD19+ cells. The differences between the unmutated and mutated subgroups and between the CD38+and the CD38 subgroups are significant (P < .001). In addition, the differences between the unmutated subgroup and the normal CD5+ B cells, and between the CD38+ subgroup and the normal CD5+ B cells, are also significant (P < .001).

Fig. 5.

Comparison of density of HLA-DR expression on B-CLL cells and normal CD5+ B cells.

PBMCs from 61 B-CLL cases and 20 age-matched normal donors were analyzed for the expression of HLA-DR on CD5+CD19+ cells. Bars represent the mean ± SE of the MFIR of HLA-DR expression on CD5+CD19+ cells. The differences between the unmutated and mutated subgroups and between the CD38+and the CD38 subgroups are significant (P < .001). In addition, the differences between the unmutated subgroup and the normal CD5+ B cells, and between the CD38+ subgroup and the normal CD5+ B cells, are also significant (P < .001).

Close modal

CD69 and CD71 are indicators of cellular activation that follow different kinetics of expression. CD69 is expressed very quickly (within 4 hours) after cell triggering, whereas CD71 is expressed much later.23-25 Since the unmutated B-CLL cases contain significantly higher percentages of CD69+ cells and lower percentages of CD71+ cells than the mutated group (Figure4), we determined the ratio of CD69 to CD71 expression in the 2 groups. When the IgM+ and IgG+ cases were analyzed together, a significant difference in the CD69-to-CD71 ratios was found (P < .0001). When the IgM+ and IgG+ cases were analyzed separately, the IgM+B-CLL cases exhibited this difference (P < .0001), whereas the IgG+ cases did not. This discordance may reflect the limited number of isotype-switched samples available for study (n = 10).

When we plotted the percentages of cells expressing these 2 markers in each individual B-CLL case, we observed strikingly different patterns. In general, a reciprocal relationship was found between CD69 and CD71 expression (Figure 6). In approximately 80% of unmutated cases, the percentage of CD69+ B-CLL cells was higher than that of CD71+cells; in contrast, only approximately 20% of mutated cases showed a higher percentage of CD69 expression.

Fig. 6.

Expression of CD69 and CD71 by B-CLL cells from unmutated and mutated cases.

PBMCs from 61 B-CLL cases were analyzed specifically for the expression of CD69 and CD71 on CD5+CD19+ cells. The percentages of CD5+CD19+ cells expressing CD69 or CD71 were plotted independently in each of the 2 adjacent scattergrams. The symbol representing the percentage of cells expressing CD69 is connected with a line to the symbol representing the percentage of cells expressing CD71 in each individual unmutated (left panel) and mutated case (right panel). Overall, the percentages of cells expressing CD69 inversely correlated with those expressing CD71 (P < .001).

Fig. 6.

Expression of CD69 and CD71 by B-CLL cells from unmutated and mutated cases.

PBMCs from 61 B-CLL cases were analyzed specifically for the expression of CD69 and CD71 on CD5+CD19+ cells. The percentages of CD5+CD19+ cells expressing CD69 or CD71 were plotted independently in each of the 2 adjacent scattergrams. The symbol representing the percentage of cells expressing CD69 is connected with a line to the symbol representing the percentage of cells expressing CD71 in each individual unmutated (left panel) and mutated case (right panel). Overall, the percentages of cells expressing CD69 inversely correlated with those expressing CD71 (P < .001).

Close modal

Phenotypic differences in B-CLL cases grouped by CD38 expression

We previously reported that B-CLL cases can be subdivided into 2 groups on the basis of the percentage of leukemic cells that express CD38.8 26 Therefore, we subdivided our patients on the basis of CD38 expression (CD38+ for 30% or more CD38-expressing cells; CD38 for 30% or fewer CD38-expressing cells) and reanalyzed the surface marker expression data.

A significantly higher percentage of the CD38+ cases expressed CD40, CD69, and CD79b (Figure7). In addition, the density of expression of HLA-DR by the CD38+ group was significantly higher compared with the CD38 group (P < .01; Figure 5); these results were similar to those obtained when the cases were segregated with the use of immunoglobulin V gene mutation status as the discriminating criterion.

Fig. 7.

Comparison of surface membrane phenotypes of IgM+ B-CLL cases grouped on the basis of CD38 expression.

PBMCs from 51 IgM+ B-CLL cases were analyzed for the expression of CD38, CD40, CD69, CD79b, and HLA-DR on CD5+CD19+ cells. The B-CLL cases were segregated into 2 groups: CD38+, in which 30% or more CD5+CD19+ B cells expressed CD38, and CD38, in which 30% or fewer CD5+CD19+ B cells expressed CD38. The mean ± SE of the percentages of CD5+CD19+ cells expressing CD40, CD69, or CD79b in the CD38+ and CD38 cases are provided.

Fig. 7.

Comparison of surface membrane phenotypes of IgM+ B-CLL cases grouped on the basis of CD38 expression.

PBMCs from 51 IgM+ B-CLL cases were analyzed for the expression of CD38, CD40, CD69, CD79b, and HLA-DR on CD5+CD19+ cells. The B-CLL cases were segregated into 2 groups: CD38+, in which 30% or more CD5+CD19+ B cells expressed CD38, and CD38, in which 30% or fewer CD5+CD19+ B cells expressed CD38. The mean ± SE of the percentages of CD5+CD19+ cells expressing CD40, CD69, or CD79b in the CD38+ and CD38 cases are provided.

Close modal

However, the expression of CD39, CD62L, and CD71 was not different in the CD38+ and CD38 groups; this contrasts with the results obtained when the cases were segregated according to immunoglobulin V gene mutation status. Nevertheless, the ratios of CD69-to-CD71 expression were significantly different in the CD38 subgroups (P < .001 for all B-CLL cases; P < .01 for IgM+ B-CLL cases), as was seen when the cases were compared on the basis of V gene mutation.

The preceding data demonstrate that the leukemic cells from all B-CLL cases studied differ significantly in their surface membrane phenotypes from normal antigen-naive and resting CD5+ B cells. Indeed, the phenotypic picture that emerges is that B-CLL resembles the clonal expansion of mature antigen-experienced (not naive) B lymphocytes and that these leukemic cells exhibit an activated (not resting) state that is more advanced than that of normal circulating CD5+ B cells from age-matched controls.

B-CLL cells from all cases display an activated surface membrane phenotype

B-cell activation is generally accompanied by changes in the cell surface expression and/or density of certain critical functional molecules. Since our studies indicate that B-CLL cells from all cases express the classical activation markers CD23, CD25, CD69, and CD71 (albeit in varying degrees; see below), these cells clearly display an activated surface membrane phenotype. Furthermore, the increased density of expression of CD5 and CD27 on B-CLL cells (Figure 3) is in line with the activation hypothesis, since the level of both of these markers can be up-regulated upon cellular activation.27-30 Additional support for this hypothesis comes from data indicating that B lymphocytes from B-CLL patients express CD23 and other activation or costimulatory molecules and receptor/counter-receptor pairs16-18,31-33 and can express intracellular signaling intermediates.12-14 

The reduction in the percentage of positivity and density of expression of CD22, CD32, CD79b, and IgD (Figures 2-3) is also consistent with cellular activation. B cells stimulated via the B-cell antigen receptor (BCR) down-regulate CD79b, either by modulating transcription or by splicing of messenger RNA.34,35 Furthermore, the reduced smIgD-to-smIgM ratio reported here may also reflect activation-induced modulation since mature B cells that coexpress IgM and IgD down-regulate IgD upon BCR signaling.36,37 Indeed, B-CLL cells from most patients exhibit diminished levels of surface immunoglobulin.38-41 

Of interest is the reduced expression of CD22 and CD32 (Figures 2-3; Bourgois et al36; Merson and Brochier39), molecules that participate in the negative regulation of BCR-mediated42-45 and CD38-mediated46responses. Since B cells down-regulate CD22 and probably FcγRIIb after BCR-mediated B-cell activation47,48 and/or cytokine exposure,49-51 the finding of decreased expression of CD22 and FcγRIIb strengthens the concept that B-CLL cells are triggered and consequently lose these regulatory molecules. Our observations are in line with previous studies indicating decreased levels of surface membrane CD22.40,52 53 

B-CLL cases that differ in immunoglobulin V gene mutation status also differ in activation phenotype

In addition to documenting the activated state of the leukemic cells of B-CLL cases as a whole, we have identified differences between the B-CLL subgroups defined by immunoglobulin V gene mutations. The V gene unmutated subgroup contains more cells expressing CD38, CD69, and CD40 and fewer cells expressing CD71, CD62L, and CD39 (Figure 4). In addition, the cells in this group express considerably more HLA-DR than the mutated group (Figure 5).

The time interval between cellular activation and the modulation of these markers differs considerably among normal B cells, in that the up-regulation of CD69 and HLA-DR and the down-regulation of CD62L occur more proximally to the inductive stimulus than the up-regulation of CD71.23-25 54 The strong inverse correlation between CD69 and CD71 expression (P < .001) by the unmutated versus the mutated subgroups (Figure 6) supports the notion that these subgroups approximate cells that differ in the interval since cellular triggering, with the unmutated group resembling B cells at an earlier state of activation than the mutated group.

Finally, our criterion for assigning a B-CLL case to the mutated category (ie, a 2% or greater difference from the most similar germ line gene counterpart) is based on a convention decided upon several years ago when the degree of polymorphism of the human VHlocus was less rigorously understood. Since this locus has now been sequenced, it may be reasonable to set the cutoff for this category at 1% or greater difference from the most similar germ line gene. Among the cohort of B-CLL patients studied here, 4 (all IgM+) exhibited mutations in the 1% to 2% range; these would be considered mutated if the cutoff were moved to a 1% or greater difference. Nevertheless, when we did a statistical analysis of our cases using a 1% mutation as the cutoff point, essentially the same significant differences in marker expression were observed as when we considered 2% mutation as the cutoff. Specifically, the percentage of B-CLL cells expressing CD38, CD39, CD40, CD69, and CD71 in patients with less than a 1% difference from the most similar germ line gene was significantly different from the patients with a 1% or greater difference (P < .05 for all). The difference in the percentage of B-CLL cells expressing CD62L among these 2 groups, however, did not achieve statistical significance with the 1% cutoff (P = .14). Furthermore, the difference in the density of expression of HLA-DR by the CLL cells of these 2 groups also remained statistically significant when the 1% cutoff was used (P < .05).

B-CLL cases that differ in CD38 expression also differ in activation phenotype

Since CD38 expression defines 2 groups of B-CLL cases8 that follow different clinical courses,8 55 we also analyzed our data to determine if a correlation exists between CD38 expression and a composite surface membrane phenotype.

The CD38+ cases show significantly more B-CLL cells expressing CD40, CD69, and CD79b (Figure 7) and a higher density of expression of HLA-DR as compared with the CD38group (Figure 5). Although the CD38 group did not show an increase in CD71 expression, the ratios of CD69 to CD71 expression were significantly different in the 2 CD38 subgroups (P < .01; data not shown).

When these results were compared with those based on V gene mutation status, the B-CLL cells in the CD38+ group resembled the unmutated group with respect to CD40 and CD69 expression and the ratios of CD69 to CD71 expression. However, they differed in regard to CD39, CD62L, and CD79b expression. These results are consistent with the idea that these 2 sets of subgroups overlap but are not identical.8,9 26 The major phenotypic feature that discriminates the CD38+ from the CD38subgroup and the unmutated from the mutated subgroup is the expression of markers indicative of temporal differences in cellular activation and possibly of the mechanisms leading to activation.

B-CLL cases do not appear to be antigen-naive

The assignment of the mutated cases to the memory compartment seems incontrovertible since these cells express significant numbers of immunoglobulin V gene mutations that are markers of BCR triggering and antigen encounter. However, since CD27 is a memory cell marker,56-58 the presence of very large numbers of CD27+ cells (approximately 90%) in all B-CLL cases demonstrated in this study (Figure 1) and others59-61implies that all B-CLL cases resemble antigen-experienced and “memory” B lymphocytes. Indeed, it is intriguing to consider the possibility that the expression of CD27 as well as the down-regulation of CD22, FcγRIIb, CD79b, and IgD (Figure 2) on the unmutated cases is also a reflection of previous triggering and memory. If so, then it is necessary to consider why these cases lack, or have very few, immunoglobulin V gene mutations. There are several possibilities. For example, these B cells may not have developed mutations because the appropriate mutational machinery was not activated. This could result because (1) the B cells were stimulated by antigens that could not turn on the mutation machinery and/or the germinal center reaction (eg, by T-cell–independent antigens, including autoantigens or other autologous structures); (2) the B cells were activated in a T-cell–dependent manner but were transformed before entering a germinal center; or (3) the B cells, after transformation, were prevented from participating in the germinal center reaction. Alternatively, these cases could have arisen from B cells that were activated and subsequently selected by antigens that are most reactive with unmutated immunoglobulin V genes. The CD38 data support the first possibility since CD38 can be expressed with cellular activation59,60 and induced by T cell–independent stimuli,30 whereas the restricted VH CDR3 features that are characteristic of the unmutated B-CLL cases7,62 63 support the last possibility.

Concluding considerations

All of the above conclusions are based on the hypothesis that the surface membrane phenotypes of B-CLL cells reflect their antigenic and activation experiences. Nevertheless, we cannot rule out the possibility that the expression of these marker proteins is a consequence of genetic abnormalities that occurred during leukemic transformation. However, if this is the case, then either different transformation mechanisms exist for the 2 subgroups or a common transforming event exists that is accompanied by other variables (such as in vivo activation) as an explanation for the differences in marker expression. Further studies will be necessary to clarify this issue.

We thank Ms Cathy Rapelje and Ms Grace Lee for performing flow cytometric analyses.

Supported in part by US Public Health Service grants CA81554, CA87956, and AI 10811 from the National Institutes of Health; the Jean Walton Fund for Lymphoma and Myeloma Research; the Joseph Eletto Leukemia Research Fund; the Sass Foundation for Medical Research; and the Richard and Nancy Leeds Fund of North Shore University Hospital.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Caligaris-Cappio
F
Gottardi
D
Alfarano
A
et al
The nature of the B lymphocyte in B-chronic lymphocytic leukemia.
Blood Cells.
19
1993
601
613
2
Bennett
JM
Catovsky
D
Daniel
MT
et al
Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.
J Clin Pathol.
42
1989
567
584
3
Coffman
RL
Cohn
M
The class of surface immunoglobulin on virgin and memory B lymphocytes.
J Immunol.
118
1977
1806
1815
4
Schroeder
HW
Jr
Dighiero
G
The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire.
Immunol Today.
15
1994
288
294
5
Hashimoto
S
Dono
M
Wakai
M
et al
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.
J Exp Med.
181
1995
1507
1517
6
Oscier
DG
Thompsett
A
Zhu
D
Stevenson
FK
Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities.
Blood.
89
1997
4153
4160
7
Fais
F
Ghiotto
F
Hashimoto
S
et al
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
J Clin Invest.
102
1998
1515
1525
8
Damle
RN
Wasil
T
Fais
F
et al
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood.
94
1999
1840
1847
9
Hamblin
TJ
Davis
Z
Gardiner
A
Oscier
DG
Stevenson
FK
Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood.
94
1999
1848
1854
10
McHeyzer-Williams
MG
McLean
MJ
Lalor
PA
Nossal
GJ
Antigen-driven B cell differentiation in vivo.
J Exp Med.
178
1993
295
307
11
Zan
H
Cerutti
A
Dramitinos
P
Schaffer
A
Li
Z
Casali
P
Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation.
J Immunol.
162
1999
3437
3447
12
Delmer
A
Ajchenbaum-Cymbalista
F
Tang
R
et al
Overexpression of cyclin D2 in chronic B-cell malignancies.
Blood.
85
1995
2870
2876
13
Schuh
K
Avots
A
Tony
HP
Serfling
E
Kneitz
C
Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients.
Leuk Lymphoma.
23
1996
583
592
14
Frank
DA
Mahajan
S
Ritz
J
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.
J Clin Invest.
100
1997
3140
3148
15
Jover
JA
Chartash
EK
Kushner
B
Friedman
SM
Crow
MK
T helper cell-induced CD23 (BLAST-2) expression: an activation marker for the high density fraction of human B cells.
Clin Immunol Immunopathol.
53
1989
99
112
16
Carlsson
M
Totterman
TH
Matsson
P
Nilsson
K
Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA.
Blood.
71
1988
415
421
17
Baldini
L
Cro
L
Cortelezzi
A
et al
Immunophenotypes in “classical” B-cell chronic lymphocytic leukemia: correlation with normal cellular counterpart and clinical findings.
Cancer.
66
1990
1738
1742
18
Sarfati
M
CD23 and chronic lymphocytic leukemia [discussion appears in Blood Cells. 1993;19:597-599].
Blood Cells.
19
1993
591
596
19
Fais
F
Ghiotto
F
Hashimoto
S
et al
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
J Clin Invest.
102
1998
1515
1525
20
Rassenti
LZ
Kipps
TJ
Lack of allelic exclusion in B cell chronic lymphocytic leukemia.
J Exp Med.
185
1997
1435
1445
21
Aisenberg
AC
Bloch
KJ
Long
JC
Cell-surface immunoglobulins in chronic lymphocytic leukemia and allied disorders.
Am J Med.
55
1973
184
191
22
Wakai
M
Hashimoto
S
Omata
M
et al
IgG+, CD5+ human chronic lymphocytic leukemia B cells: production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing.
Autoimmunity.
19
1994
39
48
23
Biselli
R
Matricardi
PM
D'Amelio
R
Fattorossi
A
Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes.
Scand J Immunol.
35
1992
439
447
24
Simms
PE
Ellis
TM
Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation.
Clin Diagn Lab Immunol.
3
1996
301
304
25
Arva
E
Andersson
B
Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae.
Scand J Immunol.
49
1999
237
243
26
Damle
R
Wasil
T
Allen
S
et al
Updated data on V gene mutation status and CD38 expression in B-CLL.
Blood.
95
2000
2456
2457
27
Bigler
RD
Bushkin
Y
Chiorazzi
N
S152 (CD27): a modulating disulfide-linked T cell activation antigen.
J Immunol.
141
1988
21
28
28
Freedman
AS
Freeman
G
Whitman
J
et al
Expression and regulation of CD5 on in vitro activated human B cells.
Eur J Immunol.
19
1989
849
855
29
Werner-Favre
C
Vischer
TL
Wohlwend
D
Zubler
RH
Cell surface antigen CD5 is a marker for activated human B cells.
Eur J Immunol.
19
1989
1209
1213
30
Zupo
S
Dono
M
Massara
R
Taborelli
G
Chiorazzi
N
Ferrarini
M
Expression of CD5 and CD38 by human CD5- B cells: requirement for special stimuli.
Eur J Immunol.
24
1994
1426
1433
31
Marti
GE
Zenger
V
Caproaso
NE
et al
Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes.
Anal Quant Cytol Histol.
11
1989
315
323
32
Schattner
EJ
Mascarenhas
J
Reyfman
I
et al
Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Blood.
91
1998
2689
2697
33
Trentin
L
Zambello
R
Sancetta
R
et al
B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.
Cancer Res.
57
1997
4940
4947
34
Hashimoto
S
Chiorazzi
N
Gregersen
P
Alternative splicing of CD79a and CD79b RNA transcripts in human B cells.
Mol Immunol.
32
1995
651
659
35
Alfarano
A
Indraccolo
S
Circosta
P
et al
An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.
Blood.
93
1999
2327
2335
36
Bourgois
A
Kitajima
K
Hunter
IR
Askonas
BA
Surface immunoglobulins of lipopolysaccharide-stimulated spleen cells: the behavior of IgM, IgD and IgG.
Eur J Immunol.
7
1977
151
153
37
Monroe
JG
Havran
WL
Cambier
JC
B lymphocyte activation: entry into cell cycle is accompanied by decreased expression of IgD but not IgM.
Eur J Immunol.
13
1983
208
213
38
Ternynck
T
Dighiero
G
Follezou
J
Binet
JL
Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies, I: detection and quantitation of light chain determinants.
Blood.
43
1974
789
795
39
Merson
A
Brochier
J
Phenotypic heterogeneity of B cell chronic lymphocytic leukaemia.
Immunol Lett.
19
1988
269
271
40
Batata
A
Shen
B
Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia: a study of 242 cases.
Cancer.
70
1992
2436
2443
41
Ludescher
C
Gattringer
C
Weger
AR
et al
Surface immunoglobulin density in the differential diagnosis of B-cell chronic lymphocytic leukemia and leukemic immunocytoma.
Leuk Res.
16
1992
191
196
42
Phillips
NE
Parker
DC
Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis.
J Immunol.
132
1984
627
632
43
Cambier
JC
Antigen and Fc receptor signaling: the awesome power of the immunoreceptor tyrosine-based activation motif (ITAM).
J Immunol.
155
1995
3281
3285
44
Nitschke
L
Carsetti
R
Ocker
B
Kohler
G
Lamers
MC
CD22 is a negative regulator of B-cell receptor signalling.
Curr Biol.
7
1997
133
143
45
Kiener
PA
Lioubin
MN
Rohrschneider
LR
Ledbetter
JA
Nadler
SG
Diegel
ML
Co-ligation of the antigen and Fc receptors gives rise to the selective modulation of intracellular signaling in B cells: regulation of the association of phosphatidylinositol 3-kinase and inositol 5′-phosphatase with the antigen receptor complex.
J Biol Chem.
272
1997
3838
3844
46
Oliver
AM
Grimaldi
JC
Howard
MC
Kearney
JF
Independently ligating CD38 and Fc gammaRIIB relays a dominant negative signal to B cells.
Hybridoma.
18
1999
113
119
47
Dorken
B
Moldenhauer
G
Pezzutto
A
et al
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes.
J Immunol.
136
1986
4470
4479
48
Jiang
Y
Hirose
S
Sanokawa-Akakura
R
et al
Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus.
Int Immunol.
11
1999
1685
1691
49
te Velde
AA
Huijbens
RJ
de Vries
JE
Figdor
CG
IL-4 decreases Fc gamma R membrane expression and Fc gamma R-mediated cytotoxic activity of human monocytes.
J Immunol.
144
1990
3046
3051
50
Van Den Herik-Oudijk
IE
Westerdaal
NA
Henriquez
NV
Capel
PJ
Van De Winkel
JG
Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes.
J Immunol.
152
1994
574
585
51
Pricop
L
Redecha
P
Teillaud
JL
et al
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines.
J Immunol.
166
2001
531
537
52
Matutes
E
Owusu-Ankomah
K
Morilla
R
et al
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
Leukemia.
8
1994
1640
1645
53
Sembries
S
Pahl
H
Stilgenbauer
S
Dohner
H
Schriever
F
Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion.
Blood.
93
1999
624
631
54
Kishimoto
TK
Jutila
MA
Butcher
EC
Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule.
Proc Natl Acad Sci U S A.
87
1990
2244
2248
55
Ibrahim
S
Keating
M
Do KA
et al
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood.
98
2001
181
186
56
Agematsu
K
Kobata
T
Sugita
K
et al
Role of CD27 in T cell immune response: analysis by recombinant soluble CD27.
J Immunol.
153
1994
1421
1429
57
Klein
U
Rajewsky
K
Kuppers
R
Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells.
J Exp Med.
188
1998
1679
1689
58
Tangye
SG
Liu
YJ
Aversa
G
Phillips
JH
de Vries
JE
Identification of functional human splenic memory B cells by expression of CD148 and CD27.
J Exp Med.
188
1998
1691
1703
59
van Oers
MH
Pals
ST
Evers
LM
et al
Expression and release of CD27 in human B-cell malignancies.
Blood.
82
1993
3430
3436
60
Ranheim
EA
Cantwell
MJ
Kipps
TJ
Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells.
Blood.
85
1995
3556
3565
61
Cerutti
A
Trentin
L
Zambello
R
et al
The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity.
J Immunol.
157
1996
1854
1862
62
Johnson
TA
Rassenti
LZ
Kipps
TJ
Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features.
J Immunol.
158
1997
235
246
63
Valetto
A
Ghiotto
F
Fais
F
et al
A subset of IgG+ B-CLL cells expresses virtually identical antigens receptors that bind similar peptides [abstract].
Blood.
92
1998
431a
64
Weinrich
V
Sondermann
P
Bewarder
N
Wissel
K
Frey
J
Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms.
Hybridoma.
15
1996
109
116

Author notes

Nicholas Chiorazzi, North Shore–Long Island Jewish Research Institute, 350 Community Dr, Manhasset, NY 11030; e-mail: nchizzi@nshs.edu.

Sign in via your Institution